Grey Fox Wealth Advisors LLC Sells 174 Shares of Merck & Co., Inc. (NYSE:MRK)

Grey Fox Wealth Advisors LLC lowered its position in Merck & Co., Inc. (NYSE:MRK) by 4.7% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 3,551 shares of the company’s stock after selling 174 shares during the quarter. Grey Fox Wealth Advisors LLC’s holdings in Merck & Co., Inc. were worth $406,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of the company. Itau Unibanco Holding S.A. purchased a new position in Merck & Co., Inc. during the second quarter valued at $39,000. Abich Financial Wealth Management LLC lifted its position in Merck & Co., Inc. by 121.8% during the second quarter. Abich Financial Wealth Management LLC now owns 326 shares of the company’s stock valued at $40,000 after purchasing an additional 179 shares in the last quarter. Quarry LP purchased a new position in Merck & Co., Inc. during the second quarter valued at $42,000. Strategic Financial Concepts LLC lifted its position in Merck & Co., Inc. by 1,475.6% during the second quarter. Strategic Financial Concepts LLC now owns 35,057 shares of the company’s stock valued at $43,000 after purchasing an additional 32,832 shares in the last quarter. Finally, Ruedi Wealth Management Inc. lifted its position in Merck & Co., Inc. by 27.7% during the second quarter. Ruedi Wealth Management Inc. now owns 397 shares of the company’s stock valued at $49,000 after purchasing an additional 86 shares in the last quarter. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Trading Down 0.2 %

Shares of NYSE MRK opened at $106.38 on Thursday. The business’s 50 day moving average is $113.86 and its two-hundred day moving average is $121.93. The company has a debt-to-equity ratio of 0.80, a current ratio of 1.47 and a quick ratio of 1.22. Merck & Co., Inc. has a 1-year low of $99.80 and a 1-year high of $134.63. The stock has a market capitalization of $269.44 billion, a P/E ratio of 118.20, a PEG ratio of 1.55 and a beta of 0.39.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, July 30th. The company reported $2.28 earnings per share for the quarter, topping the consensus estimate of $2.16 by $0.12. Merck & Co., Inc. had a return on equity of 40.69% and a net margin of 21.99%. The company had revenue of $16.10 billion for the quarter, compared to analysts’ expectations of $15.87 billion. During the same period in the previous year, the firm posted ($2.06) earnings per share. The firm’s revenue for the quarter was up 7.1% on a year-over-year basis. As a group, research analysts expect that Merck & Co., Inc. will post 7.88 EPS for the current year.

Analyst Ratings Changes

Several research firms recently weighed in on MRK. Truist Financial lowered their target price on Merck & Co., Inc. from $143.00 to $132.00 and set a “buy” rating on the stock in a research report on Wednesday, October 9th. Wells Fargo & Company lowered their target price on Merck & Co., Inc. from $140.00 to $125.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 31st. UBS Group lowered their price objective on Merck & Co., Inc. from $142.00 to $136.00 and set a “buy” rating on the stock in a research report on Wednesday, October 9th. Morgan Stanley boosted their price objective on Merck & Co., Inc. from $132.00 to $134.00 and gave the company an “equal weight” rating in a research report on Thursday, July 11th. Finally, Barclays lowered their price objective on Merck & Co., Inc. from $142.00 to $140.00 and set an “overweight” rating on the stock in a research report on Monday, October 7th. One analyst has rated the stock with a sell rating, three have given a hold rating, nine have assigned a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $131.62.

Merck & Co., Inc. Company Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.